Eur Rev Med Pharmacol Sci 2021; 25 (4): 1770-1771
DOI: 10.26355/eurrev_202102_25067

Diagnosing SARS-CoV-2 associated myositis should not rely on the profile of myositis-specific antibodies alone

J. Finsterer

Klinik Landstrasse, Messerli Institute, Vienna, Austria. fifigs1@yahoo.de

Free PDF Download

To cite this article

J. Finsterer
Diagnosing SARS-CoV-2 associated myositis should not rely on the profile of myositis-specific antibodies alone

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 4
Pages: 1770-1771
DOI: 10.26355/eurrev_202102_25067

Keywords Related articles:

  1. Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis?
  2. In the face of the SARS-CoV-2 outbreak, do people suffering from oncological disease need specific attention?
  3. Production and application of polyclonal antibodies against SARS-CoV-2 viral spike protein. Development to rapid, highly sensitive diagnosis kit for early Corona viral detection among the population
  4. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2
  5. Significant decrease of IgE antibodies after a three-year controlled study of specific immunotherapy to pollen allergens in children with allergic asthma